Bicocca Open Archive

Logo unimib boa
LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.082
AS - Asia 6.466
EU - Europa 5.286
SA - Sud America 1.070
Continente sconosciuto - Info sul continente non disponibili 418
AF - Africa 180
OC - Oceania 13
Totale 28.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.495
SG - Singapore 2.274
CN - Cina 1.425
IT - Italia 1.383
HK - Hong Kong 961
BR - Brasile 800
RU - Federazione Russa 782
VN - Vietnam 686
SE - Svezia 526
UA - Ucraina 516
DE - Germania 502
IE - Irlanda 474
CA - Canada 450
GB - Regno Unito 293
FR - Francia 224
IN - India 214
BD - Bangladesh 208
FI - Finlandia 150
AT - Austria 135
AR - Argentina 106
KR - Corea 105
TR - Turchia 81
NL - Olanda 64
ZA - Sudafrica 63
IQ - Iraq 62
ID - Indonesia 61
MX - Messico 61
PK - Pakistan 61
JP - Giappone 59
PH - Filippine 49
DK - Danimarca 45
ES - Italia 45
CO - Colombia 40
EC - Ecuador 39
PL - Polonia 39
SA - Arabia Saudita 35
MA - Marocco 31
VE - Venezuela 28
BE - Belgio 24
UZ - Uzbekistan 24
MY - Malesia 19
JO - Giordania 18
KE - Kenya 17
PY - Paraguay 16
AE - Emirati Arabi Uniti 15
JM - Giamaica 15
CH - Svizzera 14
CR - Costa Rica 14
IR - Iran 14
CL - Cile 13
TH - Thailandia 13
TN - Tunisia 13
UY - Uruguay 13
EG - Egitto 12
AU - Australia 11
HN - Honduras 11
IL - Israele 10
RO - Romania 10
TW - Taiwan 10
AL - Albania 9
ET - Etiopia 9
EU - Europa 9
NP - Nepal 8
PE - Perù 8
SN - Senegal 8
BO - Bolivia 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
LT - Lituania 7
NI - Nicaragua 7
PS - Palestinian Territory 7
LB - Libano 6
RS - Serbia 6
AZ - Azerbaigian 5
EE - Estonia 5
OM - Oman 5
PA - Panama 5
SV - El Salvador 5
CZ - Repubblica Ceca 4
MN - Mongolia 4
TT - Trinidad e Tobago 4
AO - Angola 3
BG - Bulgaria 3
BY - Bielorussia 3
GR - Grecia 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BN - Brunei Darussalam 2
BZ - Belize 2
CI - Costa d'Avorio 2
CM - Camerun 2
CY - Cipro 2
GE - Georgia 2
GT - Guatemala 2
Totale 28.069
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.846
Ashburn 1.469
Singapore 1.264
Woodbridge 1.188
Hong Kong 937
San Jose 693
Houston 685
Fairfield 677
Jacksonville 524
Dublin 441
Chandler 414
Wilmington 402
Milan 355
Dearborn 335
New York 331
Seattle 305
Frankfurt am Main 297
Santa Clara 268
Cambridge 255
Toronto 238
Council Bluffs 229
Princeton 221
Chicago 220
The Dalles 214
Los Angeles 211
Dallas 190
Ho Chi Minh City 185
Beijing 184
Hanoi 157
Hefei 134
Vienna 122
Rome 111
Lauterbourg 109
Nanjing 109
Altamura 106
Lawrence 104
Shanghai 93
Seoul 92
Lachine 91
Boardman 81
Moscow 77
São Paulo 73
Buffalo 67
Fremont 49
Guangzhou 49
San Diego 48
Andover 46
Helsinki 44
Washington 43
Phoenix 42
Ottawa 41
London 40
Nanchang 39
Rio de Janeiro 38
Orem 35
Tokyo 35
Atlanta 34
Hebei 34
Munich 33
Changsha 31
Denver 31
Detroit 31
Brooklyn 30
Tianjin 30
Warsaw 30
Da Nang 29
Figino 29
Jakarta 29
Jiaxing 29
Shenyang 29
Montreal 28
Columbus 27
Baghdad 25
Johannesburg 25
Salt Lake City 25
Naples 24
Philadelphia 24
Chennai 23
San Francisco 23
Brussels 22
Huizen 22
Kunming 22
Nuremberg 22
Lahore 21
Pune 21
Tashkent 20
Falls Church 19
Bologna 18
Manchester 18
Norwalk 18
Ankara 17
Brasília 17
Hangzhou 17
Lissone 17
Miami 17
Quito 17
Amsterdam 16
Amman 15
Belo Horizonte 15
Haiphong 15
Totale 17.692
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 596
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 561
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 455
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 441
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 438
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 420
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 411
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 387
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 386
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 361
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 353
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 351
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 340
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 325
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 319
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 315
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 313
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 310
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 294
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 292
Synchronous early-stage endometrial and ovarian cancer 292
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 289
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 289
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 288
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 288
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 287
Fertility outcomes in stage I ovarian immature teratomas 286
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 285
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 283
Uterine leiomyosarcoma: analysis of treatment failures and survival 280
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 272
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 270
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 266
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 266
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 264
Endometriomas: Their ultrasound characteristics 258
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 253
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 251
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience 250
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 245
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 243
Endometrial stromal sarcoma: analysis of treatment failures and survival 242
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 241
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 241
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 240
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 239
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 236
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 236
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 234
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 234
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 233
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 233
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 232
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 227
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab 225
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 223
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 223
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 221
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 221
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 220
Optimal treatment of early-stage ovarian cancer 218
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 216
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 215
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 214
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 214
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 213
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 212
Color Doppler ultrasound in the preoperative assessment of adnexal masses 211
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 209
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 209
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 208
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: An Italian multicentric retrospective analysis 208
Tumor volume as risk factor for nodal diffusion in endometrial cancer 207
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 207
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 205
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 205
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 205
Antiemetic efficacy of granisetron in patients with gynecological malignancies 204
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 201
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 200
Ifosfamide in the treatment of malignant epithelial ovarian tumors 197
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 197
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 193
Clinically oriented three-step strategy for assessment of adnexal pathology 190
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 190
Brain metastases from endometrial carcinoma 188
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 187
Unilocular adnexal cysts with papillary projections but no other solid components: Is there a diagnostic method that can classify them reliably as benign or malignant before surgery? 187
Second-look laparotomy in the management of fallopian tube carcinoma 185
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer 185
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 184
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial 179
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 179
Fertility-sparing surgery in uterine leiomyosarcoma 178
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 177
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 173
Alpha-fetoprotein in the management of germ cell tumors of the ovary 171
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 167
Response to chemotherapy and Clinical Outcome of Patients with recurrent epithelial ovarian cancer after PARP inhibitor maintenance treatment: a Multicenter retrospective italina Study 167
Total neuropathy scale items as early predictors of chemotherapy‐induced peripheral neurotoxicity 163
Totale 25.592
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.740
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.740
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022939 0 0 0 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.380 38 43 77 73 181 353 264 33 133 39 19 127
2024/20253.730 195 512 192 196 303 144 268 125 329 517 318 631
2025/20269.492 860 594 763 891 1.016 511 1.147 614 823 917 567 789
2026/20272.313 461 469 1.020 363 0 0 0 0 0 0 0 0
Totale 28.515